Displaying drugs 14301 - 14325 of 14574 in total
CTS-21166
CTS-21166 is a small-molecule beta-secretase inhibitor, which is being developed as a disease-modifying treatment for Alzheimer's disease. CTS-21166 is the only BACE1 inhibitor that has passed Phase I clinical trial thus far. In 2008, CoMentis revealed this small compound as a transition-state analog inhibitor (structure is currently undisclosed) with excellent...
Investigational
Matched Description: … currently undisclosed) with excellent properties in brain penetration, selectivity, metabolic stability, and …
Ivarmacitinib
Ivarmacitinib (SHR0302) is a selective inhibitor of Janus kinase 1 (JAK1) under investigation for the treatment of various immuno-inflammatory conditions. While ivarmactinib has yet to receive marketing authorization, as of February 2022 clinical trials are ongoing or completed evaluating its use in atopic dermatitis,[L40604,L40619,L40629] ankylosing spondylitis, rheumatoid arthritis, psoriatic arthritis,...
Experimental
Investigational
Matched Description: … graft-versus-host disease,[A245653,L40599] vitiligo,[L40609] ulcerative colitis,[L40614] alopecia areata,[L40624] and …
2-((4'-HYDROXYPHENYL)-AZO)BENZOIC ACID
Experimental
PF-00446687
PF-00446687 has been investigated for the treatment of Erectile Dysfunction.
Investigational
Dipipanone
Experimental
Illicit
2,3,4,5,6-Pentafluorobenzyl Alcohol
Experimental
Balanol Analog 2
Experimental
N-[3-(aminomethyl)benzyl]acetamidine
Experimental
Diethyl 4-Methylbenzylphosphonate
Experimental
Iodobenzene
Experimental
ES-936
Experimental
AL7182
Experimental
(R)-Bicalutamide
Experimental
S-Ethyl-N-[4-(Trifluoromethyl)Phenyl]Isothiourea
Experimental
4-(2-Thienyl)-1-(4-Methylbenzyl)-1h-Imidazole
Experimental
PAS219
Experimental
4-Fluorophenethyl Alcohol
Experimental
Phenacetin
Phenacetin was withdrawn from the Canadian market in June 1973 due to concerns regarding nephropathy (damage to or disease of the kidney).
Withdrawn
Displaying drugs 14301 - 14325 of 14574 in total